The obesity drug market is creating trillion-dollar winners, but you don't have to pay premium prices for exposure. (NYSE: PFE) and Viking Therapeutics (NASDAQ: VKTX) are both relatively inexpensive compared to their opportunities in obesity. One offers a high-yield blue chip that just spent $10 billion entering the space, while the other is a pure-play biotech with late-stage programs in both injectable and oral weight-loss drugs.

Here's why these two healthcare stocks scan as no-brainer buys right now.

Image source: Getty Images.

Continue reading

Source Fool.com